Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA sets LixiLan decision date for Sanofi-Novo diabetes showdown; Eylea could outshine Bayer's sales forecasts, analyst predicts
FDA sets LixiLan decision date for Sanofi-Novo diabetes showdown; Eylea could outshine Bayer's sales forecasts, analyst predicts
FDA sets LixiLan decision date for Sanofi-Novo diabetes showdown; Eylea could outshine Bayer's sales forecasts, analyst predicts
Submitted by
admin
on February 22, 2016 - 6:08pm
Source:
Fierce Pharma
News Tags:
FDA
LixiLan
Sanofi
Novo Nordisk
Bayer
Eylea
Headline:
FDA sets LixiLan decision date for Sanofi-Novo diabetes showdown; Eylea could outshine Bayer's sales forecasts, analyst predicts
Do Not Allow Advertisers to Use My Personal information
